CN1642553A - N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症 - Google Patents

N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症 Download PDF

Info

Publication number
CN1642553A
CN1642553A CNA038068656A CN03806865A CN1642553A CN 1642553 A CN1642553 A CN 1642553A CN A038068656 A CNA038068656 A CN A038068656A CN 03806865 A CN03806865 A CN 03806865A CN 1642553 A CN1642553 A CN 1642553A
Authority
CN
China
Prior art keywords
formula
compound
compounds
chemical compound
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038068656A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·安克利夫
C·M·库克
C·D·埃尔德雷
P·M·戈尔
L·A·哈里森
M·A·哈耶斯
S·T·霍奇森
D·B·朱德
S·E·基林
X·Q·勒维尔
G·米尔斯
G·M·罗伯森
S·斯万森
A·J·沃尔克
M·维尔金森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1642553A publication Critical patent/CN1642553A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA038068656A 2002-03-28 2003-03-27 N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症 Pending CN1642553A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207449.0 2002-03-28
GBGB0207449.0A GB0207449D0 (en) 2002-03-28 2002-03-28 Novel compounds

Publications (1)

Publication Number Publication Date
CN1642553A true CN1642553A (zh) 2005-07-20

Family

ID=9933998

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038068656A Pending CN1642553A (zh) 2002-03-28 2003-03-27 N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症

Country Status (22)

Country Link
US (1) US20060058299A1 (https=)
EP (1) EP1487453B1 (https=)
JP (1) JP4490110B2 (https=)
KR (1) KR20040095347A (https=)
CN (1) CN1642553A (https=)
AR (1) AR039177A1 (https=)
AT (1) ATE454892T1 (https=)
AU (1) AU2003216905A1 (https=)
BR (1) BR0308719A (https=)
CA (1) CA2479910A1 (https=)
DE (1) DE60330952D1 (https=)
ES (1) ES2339436T3 (https=)
GB (1) GB0207449D0 (https=)
IL (1) IL163648A0 (https=)
IS (1) IS7415A (https=)
MX (1) MXPA04009458A (https=)
NO (1) NO20044098L (https=)
PL (1) PL372930A1 (https=)
RU (1) RU2004126145A (https=)
TW (1) TW200400823A (https=)
WO (1) WO2003082291A1 (https=)
ZA (1) ZA200406990B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
EP1919884A1 (en) * 2005-07-21 2008-05-14 AstraZeneca AB N-benzyl-morpholine derivatives as modulators of the chemokine receptor
AU2006293635A1 (en) * 2005-09-22 2007-03-29 Sanofi-Aventis Amino-alkyl-amide derivatives as CCR3 receptor liquids
HUP0500877A2 (en) * 2005-09-22 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
HUP0500886A2 (en) * 2005-09-23 2007-05-29 Sanofi Aventis Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use
HUP0800478A2 (en) * 2008-07-31 2010-03-01 Sanofi Aventis Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
RU2014126070A (ru) * 2011-12-01 2016-01-27 Глэксо Груп Лимитед Способы лечения и предотвращения глазных заболеваний

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562929A (en) * 1979-06-21 1981-01-13 Sumitomo Chem Co Ltd Preparation of optically active cyclopentenolone
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPH01117882A (ja) * 1987-10-30 1989-05-10 Dainippon Pharmaceut Co Ltd 複素環式カルボン酸アミド誘導体
JPH03291274A (ja) * 1990-04-09 1991-12-20 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
JPH04270272A (ja) * 1991-02-25 1992-09-25 Yoshitomi Pharmaceut Ind Ltd アミノアルキルモルホリン誘導体の製造法
TW223629B (https=) * 1992-03-06 1994-05-11 Hoffmann La Roche
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU2056800A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Heterocyclic piperidines as modulators of chemokine receptor activity
JP4717306B2 (ja) * 1999-09-14 2011-07-06 アベンティスユービー・セカンド・インコーポレイテッド Ｄ４拮抗剤として有用なチエノイソキサゾールフェノキシ非置換エチルおよびプロピル誘導体
IL155093A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
TW200400823A (en) 2004-01-16
AU2003216905A1 (en) 2003-10-13
RU2004126145A (ru) 2005-06-27
MXPA04009458A (es) 2005-07-27
DE60330952D1 (de) 2010-03-04
ES2339436T3 (es) 2010-05-20
PL372930A1 (en) 2005-08-08
GB0207449D0 (en) 2002-05-08
JP2005525390A (ja) 2005-08-25
AR039177A1 (es) 2005-02-09
EP1487453A1 (en) 2004-12-22
CA2479910A1 (en) 2003-10-09
BR0308719A (pt) 2005-01-04
EP1487453B1 (en) 2010-01-13
JP4490110B2 (ja) 2010-06-23
IS7415A (is) 2004-08-19
WO2003082291A1 (en) 2003-10-09
ZA200406990B (en) 2005-11-08
IL163648A0 (en) 2005-12-18
ATE454892T1 (de) 2010-01-15
KR20040095347A (ko) 2004-11-12
US20060058299A1 (en) 2006-03-16
NO20044098L (no) 2004-10-04

Similar Documents

Publication Publication Date Title
JP5089846B2 (ja) 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
CN1083448C (zh) 1-苯基-4-苄基哌嗪化合物多巴胺受体亚型的特异性配体(d4)
CN1119319C (zh) (－)6－氯－4－环丙基乙炔基－4－三氟甲基－1,4－二氢－2h－3,1－苯并噁嗪－2－酮的不对称合成
CN1062291A (zh) 药物
JP2004509953A (ja) 炎症性疾患の処置に有用な化合物
CN1395569A (zh) 含有哌嗪酰胺取代基的噁唑二酮硫代酰胺
CN1153511A (zh) 萘衍生物
CN1074764C (zh) 苯并噁嗪酮多巴胺d4受体拮抗剂
JP2005526807A (ja) 炎症性症状の治療においてｃｃｒ−３アンタゴニストとして使用するための、アリールアルキルウレア基により２位が置換されたモルホリン誘導体
CN1314905A (zh) 毒蕈碱性拮抗剂
CN1642553A (zh) N －{ [ ( 2 s ) － 4 － ( 3 , 4－二氟苄基 )吗啉 － 2 －基}甲基} － 2 －{ 3 － [ (甲基磺酰基 )氨基 ]苯基}乙酰胺作为ccr3拮抗剂用于治疗炎症
CN1304320A (zh) 用于治疗瘙痒的含pgd2受体拮抗剂的药物组合物
CN1374949A (zh) 毒蕈碱拮抗剂
CN1875018A (zh) 制备噻唑烷二酮的方法
CN1990470A (zh) 酞丁安衍生物及其制法和其药物组合物与用途
JP2006504626A (ja) モルホリン誘導体およびその中間体
JP2006504625A (ja) 炎症疾患治療のためのｃｃｒ−３拮抗薬として使用される２位に置換アセトアミド基を有するモルホリン誘導体
JP2005527557A (ja) 炎症性症状の治療においてｃｃｒ−３アンタゴニストとして使用するための、２位がヘテロシクリルアルキルウレア基で置換されたモルホリン誘導体
JP2005529094A (ja) 炎症性疾患の治療に有用なｃｃｒ−３拮抗薬としてのｎ−（モルホリン−２−イル）メチルアセトアミド誘導体
WO2003099798A1 (en) Morpholinylmethylureas ccr-3 receptor antagonist
CN1914174A (zh) 阿立哌唑晶形的制备方法
CN1642554A (zh) 作为ccr－3拮抗剂用于治疗炎症的吗啉脲衍生物苯磺酸盐
WO2003099287A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
CN1481245A (zh) 用于治疗单纯疱疹病毒的2－氨基苯并噁嗪酮
JP2005527564A (ja) 抗炎症性モルホリン−アセトアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication